Key result
Lifestyle modification fails to reduce metabolic syndrome drug treatment requirement scores.
Why the study?
Does lifestyle modification intervention reduce anti-metabolic syndrome drug treatment requirement in patients with metabolic syndrome-associated disorders?
RCT
Randomized
No
Does lifestyle modification intervention reduce anti-metabolic syndrome drug treatment requirement in patients with metabolic syndrome-associated disorders?
Answers are grounded in this paper and cite their sources.
Lifestyle modification did not significantly reduce the calculated anti-metabolic syndrome drug treatment requirement score, though scores trended lower in patients with good lifestyle modification.
Background: Lifestyle modification is the process of gradual adaptation of corrective lifestyle habits such as diet, physical activity, and sleep for the prevention and management of various diseases. Metabolic syndrome encompasses disorders underscored by metabolic irregularities. Nearly 25% of the global population is affected by metabolic syndrome-associated disorders (MSADs), whichaccount for most medical outpatient visits and drug prescriptions. As therapeutic adjuncts, lifestyle modification interventions may have a substantial impact on anti-metabolic syndrome drug treatment requirements for control of phenotypic expressions of MSADs. The aim of this study is to determine the combined effect of lifestyle modification on MSADs as therapeutic adjuncts. Materials and Methods: This was a longitudinal study and part of a randomized controlled trial of lifestyle modification intervention for the management of metabolic syndrome-associated disorders approved by the UNTH ethics committee. Collaborating dieticians, medical sociologists, and exercise physiotherapists assigned Lifestyle Modification Scores (LMS) of GOOD=4-5, FAIR=3, and POOR=0-2 to the patients after diet, sleep, and exercise analysis. Anti-metabolic Syndrome Drug Treatment Requirement (ADTR) score was calculated as the total number of defined unitary dosages of anti-metabolic syndrome drugs times adherence +/- 0.1 accordingly for each unitary or decimal increase/decrease from normal values of clinical/laboratory markers of metabolic syndrome-associated disorders. Results: There was no significant reduction of Actual Drug Treatment (AdhRx) and ADTR scores of study participants with good LMS, although the mean of the scores was lower than that of those with bad LMS (P > 0.05). Conclusion: We conclude that ADTR scores are useful and valid tools to assess the impact of lifestyle modification that addresses the aetiopathogenic mechanism in MSADs. This enables differentiation between control of phenotypic expression of MSADs by drugs and that due to lifestyle modification.
No takes yet. Share an insight, caveat, or question.
Chijioke et al. (2025) conducted an RCT in Metabolic syndrome-associated disorders. Lifestyle modification intervention vs. Poor lifestyle modification was evaluated on Actual Drug Treatment (AdhRx) and Anti-metabolic Syndrome Drug Treatment Requirement (ADTR) scores (p=>0.05). Lifestyle modification intervention did not significantly reduce Actual Drug Treatment and Anti-metabolic Syndrome Drug Treatment Requirement scores compared to poor lifestyle modification (P > 0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: